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Summary 
 
Biological optimization of proton therapy critically depends upon detailed evaluation of RBE 
variations along Bragg curve.  Clinically accepted RBE value of 1.1 is an oversimplification, 
which disregards the steep rise of LET at the distal end of the SOBP.  We observed significant 
cell killing RBE variations dependent upon beam modulation, intrinsic radiosensitivity and 
LET in agreement with the LEM predicted values indicating dose averaged LET as suitable 
parameter for biological effectiveness. Data have also been used to validate a RBE 
parameterized model. 
  
Abstract 
Purpose: The Biological optimization of proton therapy can only be achieved through a 
detailed evaluation of RBE variations along the full range of the Bragg curve.  The clinically 
used RBE value of 1.1 represents a broad average, which disregards the steep rise of Linear 
Energy Transfer (LET) at the distal end of the Spread-Out Bragg Peak (SOBP). With 
particular attention to key endpoint of cell survival, our work presents a comparative 
investigation of cell killing RBE variations along monoenergetic (pristine) and modulated 
(SOBP) beams using human normal and radioresistant cells with the aim to investigate the 
RBE dependence on LET and intrinsic radiosensitvity. 
Methods and Materials: Human fibroblasts (AG01522) and glioma (U87) cells were 
irradiated at six depth positions along pristine and modulated 62 MeV proton beams at the 
INFN-LNS (Catania, Italy). Cell killing RBE variations were measured using standard 
clonogenic assays and were further validated using Monte Carlo simulations and the Local 
Effect Model (LEM).  
Results: We observed significant cell killing RBE variations along the protons beam path, 
particularly in the distal region showing strong dose dependence. Experimental RBE values 
were in excellent agreement with the LEM predicted values indicating dose averaged LET 
as a suitable predictor of proton biological effectiveness. Data were also used to validate a 
parameterized RBE model. 
Conclusions: The predicted biological dose delivered to a tumor region based on the variable 
RBE inferred from the data, varies significantly with respect to the  clinically used constant 
RBE of 1.1. The significant RBE increase at the distal end suggests also a potential to 
enhance optimization of treatment modalities such as LET painting of hypoxic tumors. The 
study highlights the limitation of adoption of a constant RBE for proton therapy and suggests 
approaches for fast implementation of RBE models in treatment planning.  
Introduction 
Proton therapy is currently the fastest growing cancer treatment strategy attracting 
considerable interest from industry, the academic and the health care sector (1). Potential 
clinical advantages of proton beams are linked to the pattern of energy deposition termed the 
‘Bragg curve” which exhibits a well-defined, highly localized peak at the end of the proton 
track (2). Based upon the needs of clinical application, the Bragg peak can be spread out by 
modulating the proton energy in order to attain the desired uniform dose at depth throughout 
the target volume. The modulation in energy can be obtained by degrading or varying the 
entrance beam energy leading to superposition of several monoenergetic proton beams or 
pristine peaks of closely spaced energies known as the Spread Out Bragg Peak or SOBP (3, 
4). Using protons or ion beams, it is therefore possible to obtain more defined dose 
distributions than those produced with photon beams, sparing a larger volume of healthy 
tissues from unwanted radiation exposure. 
In addition to the favorable dose distributions made possible by the Bragg peak, successful 
implementation of any kind of ions used for radiotherapy critically depends on the relative 
biological effectiveness (RBE) (5). Whilst for energetic photons, the quality of induced 
damage does not change with depth and the total absorbed dose can be used as the main 
parameter to estimate the amount of damage produced, for charged particles the quality of 
the DNA lesions tend to become more clustered and complex along the particle track as the 
particle slows down (6). This is related to the clustering of ionizations that increases as the 
energy of the charged particles decreases. Estimation of the relative biological effectiveness 
(RBE) of proton beams compared to energetic X-rays is therefore a key issue in radiotherapy 
as any uncertainty in RBE translates directly into uncertainty of the biologically effective 
dose (i.e. physical dose ×RBE) delivered to the patient, strongly undermining the 3.5% 
requirement for dose uncertainty in clinical settings (7, 8).  
Current clinical practice adopts a constant RBE value of 1.1 across the entire SOBP 
irrespective of its size, beam modulation, depth, cellular radio-sensitivity and the delivered 
dose (9, 10). Furthermore, use of a single RBE value for protons is complicated as the RBE 
also depends on the dose per fraction, number of fractions, tissue types, level of oxygenation, 
and the biological end-point (11). In vitro studies reported proton RBE values increasing 
along the SOBP reaching 1.4-1.6 (12 - 15).  
As shown by Frese et al in a modeling study where a theoretical variable RBE value is used 
to calculate an RBE-weighted proton treatment plan, there are some significant differences 
between the biologically weighted dose and the absorbed dose distributions for both the 
tumor and normal tissues (16). It is calculated that there may be as much as 3 mm increase 
in estimated range when a variable RBE weighting is used during treatment planning (17). 
These RBE variations are more important during fractionated exposure of hypoxic tumors. 
Good understanding of the dependency of RBE on the LET parameter and therefore the beam 
modulation may lead to further optimization of LET painting as effective tumor treatment 
modality (18, 19).  
Studies carried out in the past addressing the issues of RBE variation along the proton path 
are mainly dominated by results obtained using non-human mammalian V79 cells or 
immortal human cells such as HeLa cells (20), which differ in radioresponse from the 
primary cells. Very few experiments report comparative findings from normal human 
primary and tumor cells in order to address the role of intrinsic radiosensitivity. Moreover, 
the conclusions are limited by the fact that the response was evaluated only at a few positions 
mainly mid SOBP (21, 22) and with large uncertainties on the depth positioning and therefore 
the delivered dose and LET.   A more systematic approach supported by more precise 
measurements and a comparative analysis of both monoenergetic and modulated Bragg peak 
between human normal primary and radioresistant cell lines is still needed. Such studies will 
provide critical information for clinical treatment optimization algorithms and fundamental 
data for modeling studies. 
 In this work, we studied in detail the RBE variations in cell killing in two cell lines with 
different radiosensitivity (normal human skin fibroblasts (AG01522) and radioresistant 
human glioma (U87)) at several precise positions along a 62 MeV modulated (SOBP) and 
monoenergetic (pristine) Bragg curve covering all the crucial depths-1.69, 28.21, 29.28, 
29.76, 30.24, and 30.72 mm along pristine Bragg curve and 1.52,19.22, 24.28, 30.14, 30.82 
and 31.22 mm along SOBP. Such depths correspond to positions of clinical relevance (i.e. 
entrance, proximal, central and distal end of a SOBP configuration) or where the LET 
changes rapidly (distal dose fall off of the Bragg peak in the pristine configuration). We used 
62 MeV as a starting point for higher energy studies however energies close to 60 MeV have 
been successfully used for treating ocular melanoma and other superficial tumors.  
Methods and Material 
Cell culture 
AG01522 cells were maintained in α-modified Minimum Essential Medium (MEM) (Sigma 
Aldrich) supplemented with 20% Fetal Bovine Serum (FBS) and 1% penicillin-streptomycin 
(Gibco, Life Technologies Carlsbad, CA, USA).  U87 cells were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM)-high glucose medium (Gibco, Life Technologies, 
Carlsbad, CA, USA) with 10% FBS and 1% penicillin-streptomycin.  All cells were 
incubated in 5% CO2 with 95% humidity at 37°C. A detailed description is included in 
supplementary information (www.redjournal.org). 
Proton irradiation and dosimetry 
The Super-Conducting Cyclotron at the CATANA ocular melanoma treatment facility 
(Istituto Nazionale di Fisica Nucleare (INFN), Catania, Italy) generated a 62 MeV proton 
beam.  Water equivalent depths were simulated using high-grade Poly (methyl methacrylate) 
(PMMA) beam degraders (Goodfellows Ltd, Huntingdon, England) to 10 µm precision with 
relative dose profiles obtained with a Markus™ electron ionization chamber (100 µm 
resolution). Detailed description of beam line and dosimetry has been previously published 
by Cirrone et al (23). For RBE determination, AG01522 and U87 cells at the same passage 
number were irradiated using 225 kVp X-rays (XRAD 225, Precision X-ray Inc, New Haven 
CT, USA) at a dose rate of 0.591 Gy/min in our laboratory in Queen’s University Belfast 
under similar conditions to the proton irradiations.  
Clonogenic assay 
After irradiation, cells were immediately trypsinized, counted and seeded onto six-well plates 
in duplicate with sufficient density to obtain ~50 colonies per well.  Plates were then 
incubated in 5% CO2 with 95% humidity at 37°C for 10-12 days to allow for macroscopic 
colony formation.  Colonies were fixed and stained using 0.5% crystal violet dye in 95% 
methanol in water for 30 minutes at room temperature then gently rinsed in water and air 
dried. Crystal violet stained colonies were counted manually in each duplicate well for each 
data point using Zeiss Stemi 2000 C stereomicroscope (Carl Zeiss, Germany). Colonies 
consisting of at least 50 cells were scored as viable.   
Data analysis and Simulation 
Cell survival and dose response data were fitted using the linear quadratic equation: 
 
Where SF denotes the Surviving Fraction of cells at dose D with curve fitting parameters 
α and β. Non-linear regression analysis was performed on survival curves using GraphPad 
Prism version 5.0c. RBE values were calculated relative to 225 kVp X-rays according to 
 
where RBESF is the RBE at a survival level of SF, and  and  are the X-ray and 
proton doses required to give a survival of SF, respectively. These dose values were 
calculated from the linear quadratic fit to the observed data. To allow for direct fitting of 
these dose values, and thus reduce fitting uncertainty on these terms, α and β were re-stated 
in terms of DSF and , as: 
 
allowing for DSF and γ to be obtained explicitly at each survival level.  
 LET profiles were calculated from simulations using the Geant4 Monte Carlo toolkit (24) 
with Local Effect Model (LEM) comparisons using the methods described by Krämer et al 
(25). Using the LEM, the biological effect of radiation is determined based upon the 
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local energy deposition in the cell nucleus, independent of the type of radiation.  This independence allows the prediction of particle radiation effects based on cellular response under conventional photon modalities.   
Results  
Depth dose and LET profile  
Depth, dose and LET values for the irradiation positions P1 to P6 along the 62 MeV pristine 
peak and SOBP are shown in supplementary table-1 (www.redjournal.org). Dose and LET 
profiles at various depths in water are reported in Figure 1. It is evident that although beam 
modulation causes an increase in relative dose at the entrance position P1 (~60% of the 
peak dose vs. ~20% in the monoenergetic scenario) the LET remains unchanged.  For the 
monoenergetic configuration, LET reaches 11.9 keV/µm at the position of peak dose P4 
and 22.6 keV/µm at the most distal position P6.  Similarly, LET increases across the SOBP 
reaching a peak of 25.9 keV/µm at the most distal position P6. 
Cell survival response curves 
Figure 2 shows the survival curves of AG01522 and U87 cells irradiated along the 
monoenergetic (left) and modulated (right) proton beams. X-ray survival shows relatively 
more shoulder for U87 cells (α = 0.11± 0.028 Gy-1; β = 0.06 ± 0.01 Gy-2) than for AG01522 
cells (α = 0.54 ± 0.06 Gy-1; β = 0.062 ± 0.02 Gy-2), requiring a larger dose range (0-7 Gy) 
to cover survival fractions between 0.01 and 1.  Survival curves become progressively 
steeper and more linear towards the distal region, particularly for the AG01522 cell line, 
correlating with an increasing LET and supporting the hypothesis of increased DNA 
damage complexity. 
RBE dependency on depth and dose 
Figure 3 shows the RBE comparison (SF = 50%, 10% and 1%) at various depths for both 
cell lines and dose profiles. RBE increase is apparent in all cases at the distal end, reaching 
values well above the clinically used RBE of 1.1.  Figure 3 also indicates the critical effect 
of survival level on RBE, with an almost two-fold increase in maximum RBE between the 
1% and 50% surviving fractions.  To further elaborate on the effect of proton dose on RBE 
Figure 4 plots RBE as a function of dose at each position for both cell lines. Consistent 
with the trend in Figure 3, RBE at all positions is elevated for lower doses (corresponding 
to a higher survival fraction). This is particularly evident for the normal cells and at the 
distal positions, which could have a substantial impact when considering safety margins in 
treatment planning and varying the dose per fraction. 
RBE variation as a function of LET 
Figure 5 reports RBE variation as a function of LET for both cell lines and beam 
configurations.  A clear RBE increase is observed with LET in all scenarios and, within the 
experimental uncertainties and limited LET range of protons, the data are well described 
by a linear response. Although the monoenergetic RBE values appear consistently higher 
than for the SOBP, comparisons of the data with the LEM show that despite the different 
energy spectra as shown in the Supplementary Figure 1 (www.redjournal.org), the RBE in 
both configurations is adequately described by the same linear response with the R2 value 
(co-efficient of determination indicating goodness of fit of a function) ranging from 0.82 - 
0.98. Using the clinically implemented rapid calculation method of the LEM, weighted α 
and β values based on the energy spectrum at each experimental position are used to 
calculate RBE values.  While assuming a nuclear radius ≈ 6.5 µm, in accordance with 
typical human skin fibroblast and glioma dimensions (26, 27), the threshold dose parameter 
(Dt) was optimized at 9.5 and 8 Gy by independently fitting to the experimentally obtained 
data for the AG01522 and U87 cell lines respectively. 
Parameterization of RBE 
To fully appreciate the impact of dose, LET and intrinsic radiosensitivity, the RBE can be 
parameterized. By adopting the linear quadratic formulation and the RBE definition (RBE 
= DX-ray/DProton @ isoeffect), the RBE can be expressed as a function of the α and β 
parameters and the delivered dose  
RBE = ((αx2 + 4 βx Dp (αp + βp Dp))^(1/2) – αx )) / (2  βx Dp) 
Where αx, βx, αp and βp are the α and β parameter from the X-ray and proton exposure and 
Dp is the proton delivered dose. The α and β for each position are shown in the Table-1 of 
the supplementary information available at (www.redjournal.org). Several equivalent 
expressions can be also derived. The LET dependency can be explicitly included by 
analyzing the variation of αp and βp for the different depth and LET position investigated. 
From the supplementary Figure 2 (www.redjournal.org), it is reasonable to assume that the 
α parameter varies linearly with LET in case of both monoenergetic Bragg peak and SOBP. 
However, the slope for SOBP is lower than that of pristine beam suggesting that small 
variations in the ionization clustering (i.e. LET) can result in significant effects on α 
parameter. Furthermore, the β parameter varied non-significantly with LET for both 
monoenergetic and SOBP leading to a constant β assumption in our RBE parameterization. 
For the RBE parameterization we have used an average β value estimated by averaging the 
β values for all positions (average β values for AG01522= 0.051 ± 0.038; U87 = 0.059 ± 
0.024). This is in broad agreement with the previously reported data (28-30) obtained using 
proton beams of specific energies (which in principle is different than using a 
monochromatic beam and placing samples at different depths). The α parameter is therefore 
expressed as 
αp = αx + λ LET 
whilst the β parameter is assumed to remain constant with LET (βp = βx). From the above 
equation, is also evident that small variations of the β parameter have no effect. 
The final RBE parameterization model can therefore be expressed as 
RBE = ((αx2 + 4 βx Dp (αx + λ LET + βx Dp))^(1/2) – αx )) / (2  βx Dp) 
with the λ parameter for our cell system of 0.0451 µm keV-1 Gy-1 and 0.0127 µm keV-1 
Gy-1 for the AG01522 and U87 respectively.  
To assess critical discrepancies between the experimental RBE and accepted clinical RBE, 
figure 6 compares RBE weighted dose calculated using the constant (RBE 1.1) and 
experimental variable RBE. With the application of variable RBE in the SOBP regime, 
AG0 and U87 cell lines respectively see an increase of 18.3% and 17.9% in RBE weighted 
dose in the SOBP region, extending the effective range by 130 μm and 150 μm.  The most 
marked increase occurs in the distal dose fall off region (DDF) with ~79% increase in the 
region beyond the biological dose with clinical RBE . 
Discussion 
Using a systematic approach with particular emphasis on dosimetry to assess critical 
variations, the dataset produced by this study provides a reference in the ongoing debate of 
fixed versus variable RBE in proton therapy.  Moreover, generation of radiobiological 
monoenergetic datasets will aid modeling techniques as a basis of treatment planning (31). 
In agreement with radiobiological models, data reported (figure-2) indicate that cellular 
response in terms of cell death varies along monoenergetic proton beams as well as the 
SOBP of a modulated beam, reaching the highest values towards the distal end of the Bragg 
peak (12-15). Survival curves become progressively steeper and more linear towards the 
distal region, particularly for the AG01522 cell line, correlating with a rising LET and 
supporting the hypothesis of increased damage complexity. Differences are observed 
across the SOBP with the RBE consistently higher than the clinical used value of 1.1. Using 
Hep2 cells, Britten et al reported RBE differences between proximal, middle and distal end 
of the SOBP with a value of 2.3 at distal dose fall off (22). Small differences observed in 
the RBE-LET relationship between monoenergetic and modulated beams could be 
attributed to the different energy spectra experienced by the samples for the same dose 
averaged LET. The Local Effect Model simulations are in excellent agreement with the 
experimental data and confirm that small non-significant differences between the 
monoenergetic and modulated beam are to be expected. Similar small differences between 
monoenergetic and modulated beam response were reported by Belli et al in V79 cells (12) 
and attributed to energy spectra of secondary species. However, on follow up studies using 
carbon ions, Belli et al reported that the SOBP is less effective than monoenergetic beams 
of the same dose averaged LET. The differences were also dependent on the specific cell 
line leading to the conclusion that the dose averaged LET might not be a suitable parameter 
for predicting the biological effectiveness of heavy ion beams. Under the experimental 
conditions reported in this study , the dose averaged LET appears to be a suitable parameter 
to predict RBE for cell killing along a proton beam but most likely this cannot be 
extrapolated to heavier ions like carbon. In particular considering the limited LET range 
covered in a proton beam, a linear relationship between RBE and LET appears to be valid 
for each cell model and dose level.  
It is important to note that RBE values strongly depend on the survival level at which the 
calculations are performed (i.e. absorbed dose) and cellular radio-sensitivity with larger 
values obtained for the 50% level and dramatically decreasing at the 1% level (32). This is 
particularly critical for hyper-fractionation strategies and heterogeneous cell populations 
where higher survival levels are expected following an individual radiation exposure. 
Considering that clinical radiotherapy fractions deliver ~2 Gy to tumor cells which 
correspond to survival levels in the range 30-60% for the U87 cancer cells investigated, 
the adoption of a constant RBE = 1.1 appears to be limitative and inadequate. Adopting 
RBE values calculated at the 2 Gy level (or at the level of the delivered dose/fraction) might 
be a better clinical option. The RBE-Dose relationship reported in figure 4 further indicates 
how rapidly the RBE changes with dose especially in the low dose region which would 
characterize the tumor-healthy tissue boundaries. The RBE variation effect is more marked 
in the radio-sensitive cell line (AG01522).  
The biologically effective dose profile calculated using AG01522 data obtained in this 
study, indicates an underestimation of the biologically effective dose delivered to the 
surrounding normal and tumor area of up to 24 and 37% respectively by the treatment 
employing RBE=1.1. Although extrapolation from in vitro cell line data to in vivo tissues 
is not straightforward, these results highlight the extent of potential underestimation 
resulting from the adoption of fixed RBE values. Furthermore, the distal edge of the SOBP 
might be shortened by 150 µm for radioresistant-U87 cells and 130 µm for normal 
AG01522 cells using the fixed RBE value. Such differences become even more critical for 
different fractionation modalities where the dose per fraction can be significantly lower 
than 2 Gy.   
The RBE differences observed in this study support the hypothesis that employment of 
variable RBE might lead to significant optimization of proton therapy and closer outcome 
predictions as also shown by Dasu (18). Our study also highlights how current technology 
and dosimetry can provide the necessary support for RBE measurements with an accuracy 
level suitable for clinical purposes and further extrapolation to higher energies relevant for 
treating tumors with greater volumes. Finally, the use of a monochromatic beam as 
reference appears to be a valid approach offering a useful tool and allowing comparative 
investigations.  
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Figure Legends: 
Figure 1. Dose and LET profiles for 62 MeV monoenergetic (top) and modulated (bottom) 
proton beam configurations.  Vertical lines mark cell irradiation positions P1 – P6.  Relative 
dose and GEANT4 derived dose averaged LET values are indicated in dashed and solid 
black lines respectively. 
Figure 2. Clonogenic survival data at experimental irradiation positions P1 – P6 for 
AG01522 and U87 cells in monoenergetic and modulated 62 MeV proton beam 
configurations. Error bars indicate standard error of the mean. 
Figure 3. Comparison of RBE as a function of depth along monoenergetic and modulated 
62 MeV proton beams for the normal fibroblast (AG01522, top panel) and radioresistant 
glioma (U87, bottom panel) cells.  RBE values are relative to 225 kVp X–rays using proton 
α and β values obtained using the Linear-Quadratic model. Error bars indicate standard 
error of the mean. 
Figure 4. RBE variation as a function of dose and experimental position for normal 
fibroblast (AG01552) and radioresistant glioma (U87) cells after exposure to a 
monoenergetic 62 MeV proton beam.  Lines are for visual guidance only. Error bars 
indicate standard error of the mean.  
Figure 5. RBE variation as a function of LET, comparing monoenergetic and modulated 
62 MeV proton beam configurations in normal fibroblast (AG01522, top panel) and 
radioresistant glioma (U87, bottom panel) cells at survival levels of 50%, 10% and 1%.  
Lines are for visual guidance only. Error bars indicate standard error of the mean. 
Figure 6. Comparison of RBE weighted or biological dose (the product of physical dose 
and RBE, which is expressed as Gy(RBE), calculated using clinical constant and 
experimental variable RBE values. Application of variable RBE resulted in an increase of 
RBE weighted dose in the tumor region (i.e. SOBP plateau), approximately by 18.1 % 
and 17 % for the normal AG01522 and radioresistant U87 cells respectively.  RBE 
escalations in the distal region result in 130 and 150 µm extension of the effective SOBP 
distal edge for the AG01522 and U87 cell lines. 
  






 Supplementary Information 
Materials and Methods 
Cells handling and transportation. For proton beam line experiments 80-90% confluent 
flasks were completely filled with warm (37°C) low serum (2.5%) medium, then sealed 
and packed in polystyrene foam containers.  Upon arrival at the facility, low serum medium 
was replaced with regular full growth medium specific to the respective cell lines, as 
described.  The flasks were incubated for 24 -36 hours to allow recovery from any stress 
occurring during transportation.  For each sample polystyrene slide flasks of 1mm 
thickness and growth area 9 cm2 were seeded with 3 x105 cells in 3 ml complete medium 
(Thermo Scientific Nunc, catalogue no. 170920) and incubated in 5% CO2 at 37°C 24 
hours before irradiation. Immediately before irradiation, full serum cell culture medium 
was replaced with low serum medium before being transported in a polystyrene foam box 
to the target area.  Samples were mounted in sets of 5 on a remotely controlled X-Y axis 
translator.  All samples were exposed at room temperature.. 
Proton Irradiation and Dosimetry 
Reference dosimetry was carried out using a parallel plate Markus ionization chamber 
(Advanced Markus Chamber, 0.02 cm2, type 34045, PTW, Freiberg, Germany), calibrated 
according to the standards stated by the IAEA Technical Report Series 2000 code of 
practice. Samples were irradiated at water equivalent depths simulated using high-grade 
Poly(methyl methacrylate) (PMMA) beam degraders (Goodfellows Ltd., Huntingdon 
England) to 10 µm precision.  The SOBP (11 mm plateau) was generated by the same 
modulator wheel used in routine clinical procedures.  Cells were irradiated at an average 
dose rate of 3 Gy/min with a 1.7x1.7 cm2 collimated proton beam of > 80% uniformity. 
Dosimetry and dose uniformity was further validated using Gafchromic (EBT2) film 
densitometry.  
 
X-ray Irradiation and Dosimetry 
For RBE determination AG01522 and U87 cells at the same passage number were 
irradiated using 225 kVp X-rays (XRAD 225, Precision X-ray Inc, New Haven CT, USA) 
 at a dose rate of 0.591 Gy/min in our laboratory in Queen’s University Belfast under similar 
conditions to the proton irradiations.  
 
Simulations 
The LET profile in a voxelized water phantom, representing the experimental slide flask 
assembly, was inferred from simulations using the Geant4 Monte Carlo toolkit [28]. The 
simulation geometry consisted of an accurate reconstruction of the INFN proton transport 
beamline, including all elements using the “hadrontherapy” advanced example.  Dose 
averaged LET was attained by the calculation of the local mean of the proton stopping 
power, weighted by the local energy spectrum.  105 primary events were required to give 
acceptable statistics for each simulation. 
 
Local Effect Model Calculations 
Details of the Local Effect Model (LEM) have been reported in a number of publications.  
Using the LEM, the biological effect of radiation is determined based upon the local 
energy deposition in the cell nucleus, independent of the type of radiation.  This 
independence allows the prediction of particle radiation effects based on cellular 
response under conventional photon modalities.  Using the clinically implemented rapid 
calculation method of the LEM, weighted α and β values based on the energy spectrum 
at each experimental position are used to calculate RBE values.  While assuming a 
nuclear radius ≈ 6.5 µm, in accordance with typical human skin fibroblast and glioma 
dimensions, the threshold dose parameter Dt was optimized at 9.5 and 8 Gy by 
independently fitting to the experimentally obtained data for the AG0 and U87 cell lines 
respectively. 
 
 
 
 
 
 
 
 
 Table-1 Depth, LET and survival parameters characteristics for U87 and AG01522 cells  
 
 
 
Pristine                          U87           AG01522 
 
 
SOBP U87           AG01522 
  
      
  
 
 
 
 
 
 
 
 
 
 
 
Positions 
 
 
Depth 
(mm) 
 
LET 
(keV/μm) 
 
α(Gy-1) ± Error 
 
 
β(Gy-2) ± Error 
 
 
α(Gy-1) ± Error 
 
 
β(Gy-2) ± Error  
 
 P1 
 P2 
 P3 
 P4 
 P5 
 P6 
 
1.69 
28.21 
29.28 
29.76 
30.24 
30.72 
 
1.11 ± 0.03 
4.02 ± 0.16 
7.0 ± 0.9 
11.9 ± 1.5 
18.0 ± 1.4 
22.6 ± 1.2 
 
0.14 ± 0.02 
0.17 ± 0.04 
0.22 ± 0.02 
0.44 ± 0.06 
0.77 ± 0.08 
0.90 ± 0.13 
 
0.064 ± 0.009 
0.065 ± 0.017 
0.071 ± 0.009 
0.045 ± 0.002 
0.008 ± 0.003 
0.010 ± 0.006 
 
0.75 ± 0.10 
1.02 ± 0.13 
1.29 ± 0.15 
1.70 ± 0.12 
1.87 ± 0.20 
2.43 ± 0.28 
 
0.119 ± 0.081  
0.061 ± 0.013  
0.041 ± 0.012  
0.079 ± 0.013  
0.074 ± 0.025  
0.057 ± 0.048  
 
 
Positions 
 
 
Depth 
(mm) 
 
LET 
(keV/μm) 
 
α(Gy-1) ± Error 
 
 
β(Gy-2) ± Error 
 
 
α(Gy-1) ± Error 
 
 
β(Gy-2) ± Error  
 
 P1 
 P2 
 P3 
 P4 
 P5 
 P6 
 
1.52 
19.22 
24.28 
30.14 
30.82 
31.22 
1.2 ± 0.2 
2.6 ± 0.2 
4.5 ± 0.3 
13.4 ± 1.5 
21.7 ± 1.5 
25.9 ± 2.6 
 
0.16 ± 0.04             
0.19 ± 0.04 
0.22 ± 0.04 
0.31 ± 0.08  
0.41 ± 0.09 
0.5   ± 0.07 
0.056 ± 0.015 
0.058 ± 0.051 
0.064 ± 0.016 
0.056 ± 0.035 
0.056 ± 0.042 
0.064 ± 0.033 
0.66 ± 0.07 
0.89 ± 0.11 
1.15 ± 0.09 
1.36 ± 0.09 
1.61 ± 0.12 
2.01 ± 0.22 
0.117 ± 0.005 
0.075 ± 0.008  
0.047 ± 0.007  
0.037 ± 0.009  
0.023 ± 0.013  
0.011 ± 0.002 
  
 
 
Supplementary Figure 1. Energy spectra at the different experimental positions for the 
monoenergetic (top panel) and modulated (bottom panel) 62 MeV proton beam. 
 
 
 
 
 
 
 
 
 
    
 Supplementary Figure 2. Dependence of α and β parameters on LET for normal 
fibroblast (AG01522, top panel) and radioresistant glioma (U87, bottom panel) cells 
exposed to a modulated 62 MeV proton beam. α parameter increased linearly with 
increasing LET for both U87 and AG01522 cells. No statistically significant differences 
are observed for β parameter for either monoenergetic or SOBP. 
 
 
 
